logo-24-allergan

Allergan opens new Botox plant in Westport

pharmafile | January 29, 2020 | News story | Research and Development AbbVie Ireland, Allergan AbbVie, Allergan. Abbvie 

Allergan has officially opened a new €145m facility in Westport, Ireland to boost production of Botox.

The new building rxpands Allergan’s capacity to make Botox which is the company’s top-selling product. It generates annual sales of $3.5 billion.

Westport has been Allergan’s only production site for Botox since 1994 when it was first approved to reduce face wrinkles.

Paul Coffey, Managing Director of Allergan Westport, said: “With the addition of a new microbiology and cell-based laboratory, the team here in Westport are looking forward to contributing to product innovations that will make a difference to patients’ lives all over the world.”

The expansion of the facilities will allow the company to use other strains of botulinum toxin to invent new Botox products. Coffrey added: “With the addition of a new microbiology and cell-based laboratory, the team here in Westport are looking forward to contributing to product innovations that will make a difference to patients’ lives all over the world.

“Our primary role in Westport is manufacturing, but we are also heavily involved in the late-stage development of new products that Allergan have in the pipeline. We would be hopeful that a number of those products will end up getting launched and supplied out of the Westport site.”

Allergan employs more than 1,300 people in Westport, with another 700 in Dublin and Galway. This latest move comes after the company was bought in a $63 billion takeover by AbbVie.

Conor Kavanagh

Related Content

No items found

Latest content